Investors and partnering

ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics for organ transplantation, stem cell transplantation, and gene therapy. Our lead candidate drug Siplizumab has successfully passed Phase II clinical development with potential use in multiple indications.

As a company we are constantly searching for opportunities to make the best use of our assets, and to broaden the pipeline within our area of interest, through scientific collaborations and potential partnering.

For more information about our company and how to get in touch regarding potential collaborations and partnering, please contact us at